- Title: Subtitle
- LBP-021 24-week safety and efficacy of brelovitug monotherapy for the treatment of chronic hepatitis D: data from phase 2b of AZURE-1
- Creators
- Tatyana KushnerDavid YardeniMarta DobryanskaAlina JucovDouglas T. DieterichJordan J. FeldMaia ButsashviliEkaterine DolmazashviliDragomir GerovTamar KhuchuaTarek SaadiDavid KaplanJames ParkDimitar PavlovMariana Penkova RadichevaCarla CoffinEdward J. GaneSébastien PoulinIra JacobsonMiriam LevyMark S. SulkowskiNorah TerraultKaren DoucetteNancy S. ReauSimone StrasserTomohiro TanakaAshley DuzikSusanna TanSue NaimWill GarnerCraig PaceHassan JavanbakhtNancy ShulmanSaeed Sadiq HamidCihan Yurdaydin
- Resource Type
- Abstract
- Publication Details
- Journal of hepatology, Vol.84(Supplement 1), pp.S76-S77
- DOI
- 10.1016/S0168-8278(26)00436-8
- ISSN
- 0168-8278
- Publisher
- Elsevier B.V
- Language
- English
- Date published
- 05/2026
- Academic Unit
- Health Management and Policy; Gastroenterology and Hepatology; Internal Medicine
- Record Identifier
- 9985174809002771
Abstract
LBP-021 24-week safety and efficacy of brelovitug monotherapy for the treatment of chronic hepatitis D: data from phase 2b of AZURE-1
Journal of hepatology, Vol.84(Supplement 1), pp.S76-S77
05/2026
DOI: 10.1016/S0168-8278(26)00436-8
Details
Metrics
1 Record Views